LoadingLoadingLoadingNet selling: insiders sold $4.5M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsEach bar is 100% of that source’s money. The notch marks an even split.
Lean is the direction of the latest moves. Descriptive, not advice.
Buys/Adds (3)
Citadel
$320.1M
added
Millennium
$180.4M
added
Bank of America
$294.4M
added
Sells (1)
No tracked top-trader positions in EW as of Oct 21, 18:18 UTC.
Hyperliquid positioning - not every stock is covered
Last report
Jul 23, 2026
Financial period
Q2 2026
Earnings per share
$0.74 expected
Revenue
Company release
Q3 2026 guidance
$1.63B to $1.71B
No comparable estimate
Estimates as of Oct 20, 2026
EPS expected
$0.72 to $0.77
Revenue expected
24 analysts
Last 30 days
Analysts cutting estimates
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / income | Surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 23, 2026 | $0.78 / $0.74Yahoo Finance | +5.11% beat | $1.74B No estimate | Unavailable |
| Mar 31, 2026 | Apr 23, 2026 | $0.78 / $0.73Yahoo Finance | +7.33% beat | $1.65B No estimate | Unavailable |
| Dec 31, 2025 | Feb 10, 2026 | $0.58 / $0.62Yahoo Finance | -6.27% miss | $1.57B No estimate | Unavailable |
| Sep 30, 2025 | Oct 30, 2025 | $0.67 / $0.59Yahoo Finance | +12.63% beat | $1.55B No estimate | Unavailable |
| Jun 30, 2025 | Jul 24, 2025 | $0.67 / $0.62Alpha Vantage | +8.06% beat | $1.53B No estimate | Unavailable |
| Mar 31, 2025 | Apr 23, 2025 | Unavailable | - | $1.41B No estimate | Unavailable |
| Dec 31, 2024 | Feb 11, 2025 | $0.59 / $0.55Alpha Vantage | +6.38% beat | $1.39B No estimate | Unavailable |
| Sep 30, 2024 | Oct 24, 2024 | $0.67 / $0.59Alpha Vantage | +13.56% beat | $1.35B No estimate | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $1.55B | $1.57B | $1.65B | $1.74B |
| Cost of what it sold | $345.2M | $340.6M | $359.3M | $390.6M |
| Gross profit | $1.21B | $1.23B | $1.29B | $1.35B |
| What it spent | ||||
| Research and development | $280.7M | $267.7M | $263.3M | $278.9M |
| Sales and admin | $514.6M | $602.9M | $522.2M | $561.2M |
| Other operating costs | -$10.8M | -$11.9M | -$10.9M | -$9.2M |
| Total operating expenses | $784.5M | $858.7M | $774.6M | $830.9M |
| What was left | ||||
| Operating profit | $425.1M | $370.3M | $514.7M | $519.5M |
| Profit before tax | $348.4M | $90.4M | $459.0M | $519.8M |
| Tax | $56.1M | $26.2M | $78.3M | $278.4M |
| Net profit | $291.1M | $91.2M | $380.7M | $241.9M |
| EBITDA | $387.6M | $133.1M | $499.9M | $562.2M |
This stock is trending upward.
Trend
Constructive
60 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is mixed
Kimberly-Clark’s Kenvue Buy Clears EU Review After Agreeing To Divest European Tampon Brands
Leans bearishOct 19FDA Flags High-Risk Heart Device Recall At Edwards Lifesciences After Patient Death
BearishOct 16FDA Flags High-Risk Heart Device Recall At Edwards Lifesciences After Patient Death
BearishOct 16Edwards Lifesciences Corporation $EW Stock: Assenagon Asset Management S.A. Boosts Stake
Leans bullishOct 16Zimmer Biomet (NYSE:ZBH) Share Price Crosses Below Fifty Day Moving Average - Time to Sell?
NeutralOct 16Edwards Lifesciences Corp. stock underperforms Friday when compared to competitors
Leans bearishOct 16Edwards Lifesciences Corp. stock underperforms Thursday when compared to competitors despite daily gains
Leans bearishOct 15Barrington keeps USD 95.00 target for LeMaitre Vascular stock
NeutralOct 15
